Haleon shares crater as soft flu demand hits takings

• Haleon shares fell more than 11% to 333p in early trading after the Sensodyne-to-Centrum maker trimmed its revenue growth target, previously between three and five per cent. • The FTSE 100 firm has warned repeatedly that soft cold and flu seasons are hitting sales; North America growth slowed from 3.1% to 2.5% while European revenue dipped 0.6% on weak Centrum sales. • Third-quarter organic revenue growth of 2.6% was below expectations, chief executive Brian McNamara said. • Haleon, which split from GSK in 2022, also suspended Centrum shipments to China after a change in raw material...